Δημοσίευση

Pyoderma gangrenosum in a patient with chronic granulomatous disease: A case report.

ΤίτλοςPyoderma gangrenosum in a patient with chronic granulomatous disease: A case report.
Publication TypeJournal Article
Year of Publication2017
AuthorsNanoudis, S., Tsona A., Tsachouridou O., Morfesis P., Loli G., Georgiou A., Zebekakis P., & Metallidis S.
JournalMedicine (Baltimore)
Volume96
Issue31
Paginatione7718
Date Published2017 Aug
ISSN1536-5964
Λέξεις κλειδιάAdult, Diagnosis, Differential, Granulomatous Disease, Chronic, Humans, Male, Pyoderma Gangrenosum, Ulcer
Abstract

RATIONALE: The simultaneous occurrence of pyoderma gangrenosum (PG) and chronic granulomatous disease (CGD) is uncommon and few cases have been reported worldwide.PATIENT CONCERNS: PG is a rare, chronic, ulcerative, neutrophilic skin disease of unknown etiology that requires immunosuppressive treatment. CGD belongs to Primary Immune Deficiencies in which the main defect lies in an inability of the phagocytic cells to generate superoxide making patients susceptible to serious, potentially life-threatening bacterial and fungal infections.DIAGNOSES: In this manuscript, we present a case of ulcerative pyoderma gangrenosum in a 28-year-old man with recent diagnosis of chronic granulomatous disease during hospitalization for resistant pulmonary tuberculosis complicated with Aspergillus infection.INTERVENTIONS: Second-line therapy with dapsone and intravenous immunoglobulin was initially administered but eventually corticosteroids were added to treatment because of disease progression and further ulceration.OUTCOMES: Patient's ulcers were gradually healed with no side effects.LESSONS: Corticosteroids could be used under close monitoring for the treatment of PG in a patient with CGD, despite the increased risk for infections.

DOI10.1097/MD.0000000000007718
Alternate JournalMedicine (Baltimore)
PubMed ID28767612
PubMed Central IDPMC5626166

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.